Histopathological landscape of rare oesophageal neoplasms

Businello, Gianluca; Pozzo, C.; Sbaraglia, Marta; Mastracci, Luca; Milione, Massimo; Saragoni, Luca; Grillo, Federica; Parente, Paola; Remo, Andrea; Bellan, Elena; Cappellesso, Rocco; Pennelli, Gianmaria; Michelotto, Mauro; Fassan, Matteo

doi:10.3748/wjg.v26.i27.3865

Cited by 5 publications

(6 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High molecular weight cytokeratins are more sensitive than low molecular weight cytokeratins, but the most sensitive marker of epithelial differentiation is EMA 102 . S100 positivity is reported between 30-60% of SS, while positivity for CD34 is extremely rare 35 , 103 .…”

Section: Tumours With Uncertain Differentiationmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal tumours of the gastrointestinal tract

et al. 2021

Self Cite

View full text Add to dashboard Cite

Summary Mesenchymal tumours represent a heterogenous group of neoplasms encopassing benign, intermediate malignancy, and malignant entities. Sarcomas account for approximately 1% of human malignancies. In consideration of their rarity as well as of intrinsic complexity, diagnostic accuracy represents a major challenge. Traditionally, mesenchymal tumours are regarded as lesions the occurrence of which is mostly limited to somatic soft tissues. However, the occurrence of soft tissue tumours at visceral sites represent a well recognized event, and the GI-tract ranks among the most frequently involved visceral location. There exist entities such as gastrointestinal stromal tumours (GIST) and malignant gastointestinal neuroectodermal tumors that exhibit exquisite tropism for the GI-tract. This review will focus also on other relevant clinico-pathologic entities in which occurrence at visceral location is not at all negligible.

show abstract

Section: Tumours With Uncertain Differentiationmentioning

confidence: 99%

“…Approximately 80% of cases are deep-seated 33 , 34 . SFTs have been described in different parts of the GI tract, liver and pancreas included 35-38 .…”

Section: Neoplasm With Fibroblastic/myofibroblastic Differentiationmentioning

confidence: 99%

Mesenchymal tumours of the gastrointestinal tract

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…NENs of the esophagus are treated with surgery, chemotherapy, radiotherapy, or a combination of these modalities depending on the stage and the extent of disease. 27,28 Also, targeted endocrine treatments in patients with endocrine hormone symptoms are available. 28 The treatment regimens are being evaluated as new studies emerge.…”

Section: Discussionmentioning

confidence: 99%

“…Discriminating ACs from NENs of the EGJ is important because of differences in therapeutic strategies, follow-up, and prognosis. NENs of the esophagus are treated with surgery, chemotherapy, radiotherapy, or a combination of these modalities depending on the stage and the extent of disease 27,28. Also, targeted endocrine treatments in patients with endocrine hormone symptoms are available 28.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Staining With Neuroendocrine Markers is Essential in the Diagnosis of Neuroendocrine Neoplasms of the Esophagogastric Junction

Jepsen

Fiehn

Garbyal

et al. 2021

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) of the esophagogastric junction (EGJ) are uncommon and the classification of these tumors has been revised several times. Since 2016, at the Department of Pathology, Rigshospitalet, Denmark, all adenocarcinomas and poorly differentiated carcinomas of the EGJ have been stained routinely with the neuroendocrine markers, synaptophysin and chromogranin A, to detect a possible neuroendocrine component. This study aimed to determine if routine immunohistochemical staining is necessary to detect neuroendocrine differentiation of the EGJ tumors by evaluating how often a neuroendocrine component of the tumors was correctly identified or missed on routine hematoxylin and eosin-stained slides, and by evaluating the interobserver agreement among several pathologists. Of 262 cases a NEN was identified in 24 (9.2%). Up to 22.7% of all EGJ NENs would have been missed without routinely performed neuroendocrine staining in all EGJ tumors. The interobserver agreement between 3 pathologists was slight to moderate. In conclusion, immunohistochemical staining with neuroendocrine markers is essential for the diagnosis of NENs, and to detect all NENs, we recommend to perform this routinely on all resected tumors of the EGJ.

show abstract

“…The five‐year overall survival rate is only 15%–25% (Pennathur et al, 2013; Smyth et al, 2017). Adenocarcinoma and esophageal squamous cell carcinoma are two main pathological types, with different etiologies and different regional patterns of pathogenesis, and squamous carcinoma is the main pathological subtype (Businello et al, 2020). At present, multi‐mode treatment is adopted for esophageal squamous carcinoma, and great progress has been made in surgery and neoadjuvant/adjuvant chemotherapy (Matsuda et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Acacetin restrains the malignancy of esophageal squamous carcinoma cells via regulating JAK2/STAT3 pathway

Wang

Zhang

2023

Chem Biol Drug Des

View full text Add to dashboard Cite

Acacetin is a natural flavonoid compound found in diverse plants, which has strong anti‐inflammatory and anti‐cancer activities. This work aimed at investigating how acacetin functions on esophageal squamous carcinoma cells. In this work, esophageal squamous carcinoma cell lines were subjected to increasing doses of acacetin, and the proliferative, migrative, invasive and apoptotic phenotypes were evaluated by a series of in vitro experiments. Genes related to acacetin and esophageal cancer were predicted by bioinformatics analysis. The levels of apoptosis‐relevant proteins and JAK2/STAT3 pathway‐relevant proteins in esophageal squamous carcinoma cells were probed by Western blot. It was revealed that acacetin could block the growth and aggressiveness of TE‐1 and TE‐10 cells and promote the apoptosis. Acacetin treatment induced bax's expression and repressed bcl‐2's expression. Notably, acacetin inhibits JAK2/STAT3 pathway in esophageal squamous carcinoma cells. In summary, acacetin inhibits the malignant progression of esophageal squamous carcinoma via restraining JAK2/STAT3 signaling.

show abstract

Histopathological landscape of rare oesophageal neoplasms

Cited by 5 publications

References 141 publications

Mesenchymal tumours of the gastrointestinal tract

Mesenchymal tumours of the gastrointestinal tract

Immunohistochemical Staining With Neuroendocrine Markers is Essential in the Diagnosis of Neuroendocrine Neoplasms of the Esophagogastric Junction

Acacetin restrains the malignancy of esophageal squamous carcinoma cells via regulating JAK2/STAT3 pathway

Contact Info

Product

Resources

About